Anna Alperovich

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Prophylactic dex at absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity; dex attenuated facial nerve palsy, but not IEC-DNT, -PKS, -NP: https://t.co/pSngNexASn. #mmsm

[ASTCT @ASTCT]

A recent single-center retrospective study, published in @ASTCT_Journal, investigated post-transplant outcomes in patients with TP53-mutated or 17p-deleted myeloid malignancies treated with alloHCT. Learn more: https://t.co/oW08m0lthU

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology PD-1–based combinations before autologous #transplant are associated with improved outcomes in classical #Hodgkin #lymphoma #lymsm #bmtsm https://t.co/RGpqov2TOF

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology @QueraltSalas (⁦@hematoclinicbcn⁩): Tele-prehabilitation for allogeneic Hematopoietic Stem Cell Transplantation via ⁦@TheLancetHaem⁩ Haematology #telemedicine #frailty #geriheme #bmtsm ⁦@GETH_info⁩ ⁦@sehh_es⁩ https://t.co/QA3BcoQXM2

[Kate Cwynarski @CwynKate]

Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL

⁦@BloodPortfolio⁩
American Society of Hematology https://t.co/HaC9oCuw2D

[Kate Cwynarski @CwynKate]

How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide

⁦@BloodPortfolio⁩

American Society of Hematology https://t.co/PW1bdPNVRW

[IACH @TheIACH]

👂𝘛𝘶𝘯𝘦 𝘪𝘯 𝘵𝘰 𝘵𝘩𝘦 𝘭𝘢𝘵𝘦𝘴𝘵 𝘐𝘈𝘊𝘏 𝘕𝘦𝘸𝘴 𝘱𝘰𝘥𝘤𝘢𝘴𝘵 𝘦𝘯𝘵𝘪𝘵𝘭𝘦𝘥:

𝗧𝗶𝗺𝗲 𝗼𝗳 𝗗𝗮𝘆 𝗼𝗳 𝗖𝗔𝗥 𝗧-𝗖𝗲𝗹𝗹 𝗜𝗻𝗳𝘂𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗶𝗻 𝗟𝗮𝗿𝗴𝗲 𝗕-𝗖𝗲𝗹𝗹 𝗟𝘆𝗺𝗽𝗵𝗼𝗺𝗮
𝘣𝘺 𝘗𝘳𝘰𝘧. 𝘙𝘰𝘯𝘪 𝘚𝘩𝘰𝘶𝘷𝘢𝘭
👇👇
https://t.co/f350q28V7G

𝘊𝘭𝘪𝘤𝘬 𝘧𝘰��� 𝘵𝘩𝘦 𝘢𝘣𝘴𝘵𝘳𝘢𝘤𝘵👇
https://t.co/827Qhs0n62

@RShouval @Mohty_EBMT @nagler_EBMT

[COSTEM Congress @COSTEMCongress]

⏰ Reminder! One week to go - Special COSTEM Webinar

💬 Controversy: Is survival prolonged if we use CAR-T in second-line rather than third-line treatment in DLBCL?

📅 Nov 25, 2025 | 07:00 PM (CET)
🔗 Register free: https://t.co/jdvs8BRcOj
@NicoGagelmann

[sganguly @bmtdoc63]

Ongoing diarrhea after CAR T? Think IEC-Colitis. But rule out other infectious causes of diarrhea before starting steroid. Scope and biopsy will be necessary. In refractory cases try Infliximab or Vedolizumab. Not Tocilizumab. https://t.co/3eBvGJqcaA

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Remission Assessment by Circulating Tumor DNA #ctDNA in Large B-cell #Lymphoma #DLBCL | Journal of Clinical Oncology ⁦@JCO_ASCO⁩ #lymsm https://t.co/NJy2jAd5vd

[Khushali Jhaveri @JhaveriKhushali]

🚨 New DESCAR-T data: In 2L DLBCL, response to bridging therapy before axi-cel CAR-T predicted better survival.
Holding/BT isn’t just a placeholder—it shapes outcomes.
47% responded; responders had significantly better OS & EFS.
#ICML2025 #lymsm

[Alfredo Rivas-Delgado @arivasdelgado]

Dr. Palomba on liso-cel in 3L+ R/R MZL:
- ORR 95%, CR 62%
- 2y estimated PFS: 85.7%
- CRS in 76% (4% grade ≥3)
- Very promising for this challenging population
@MSK_DeptOfMed #18ICML

[IACH @TheIACH]

🎥 𝗖𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 @TheIACH 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗖𝗹𝘂𝗯 𝗼𝗻 𝗱𝗲𝗺𝗮𝗻𝗱!

𝗖𝘆𝗰𝗹𝗼𝗽𝗵𝗼𝘀𝗽𝗵𝗮𝗺𝗶𝗱𝗲 𝗥𝗲𝗱𝘂𝗰𝗲𝘀 𝗡𝗼𝗻-𝗜𝗖𝗔𝗡𝗦 𝗡𝗲𝘂𝗿𝗼𝘁𝗼𝘅𝗶𝗰𝗶𝘁𝘆 𝗔𝗳𝘁𝗲𝗿 𝗖𝗶𝗹𝘁𝗮𝗰𝗮𝗯𝘁𝗮𝗴𝗲𝗻𝗲 𝗔𝘂𝘁𝗼𝗹𝗲𝘂𝗰𝗲𝗹l

𝘍𝘦𝘢𝘵𝘶𝘳𝘪𝘯𝘨: 𝘋𝘳. 𝘉𝘩𝘢𝘨𝘪𝘳𝘢𝘵𝘩𝘣𝘩𝘢𝘪 𝘋𝘩𝘰𝘭𝘢𝘳𝘪𝘢, 𝘋𝘳. 𝘔𝘢𝘵𝘵𝘩𝘦𝘸 𝘍𝘳𝘪𝘨𝘢𝘶𝘭𝘵 & 𝘗𝘳𝘰𝘧. 𝘔𝘰𝘩𝘢𝘮𝘢𝘥 𝘔𝘰𝘩𝘵𝘺

📺 𝘞𝘢𝘵𝘤𝘩 𝘵𝘩𝘦 𝘧𝘶𝘭𝘭 𝘸𝘦𝘣𝘪𝘯𝘢𝘳 𝗙𝗥𝗘𝗘 𝘩𝘦𝘳𝘦:
⬇️⬇️
https://t.co/V9kMZzR1ZO

@MJFzeta @DholariaMD @Mohty_EBMT

[Mehdi Hamadani, MD @MediHumdani]

One-size does not fit all: If you ever happen to see a LBCL with excellent chemosensitivity: Auto in those circumstance still reasonable. @FateehaFurqan extends our previous work now to MYC rearranged LBCL @cibmtr #bmtsm
https://t.co/EoyIgu47rU

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

New ASTCT guidelines provide recommendations for managing and preventing non-Aspergillus molds in #HCT recipients. Developed in partnership with the ASTCT Transplant Infectious Disease SIG, this resource covers risk factors, diagnosis and treatment. https://t.co/rdpVeYQQTj

[Felipe Peña-Muñoz @HematoRules]

Congratulations @QueraltSalas et al @hematoclinicbcn @hospitalclinic for this @TheEBMT @Nature publication!

#HematoSpain #HematoEnRed @sehh_es @SEHHJoven

https://t.co/hHfd4TPqxl

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Study of conditioning, cell dose, schedule & AL #amyloidosis ASCT outcome finds full-dose MEL, no rest day & infused CD34 ≥4.5×106/kg -> superior OS; higher TRM if poor PS, hi NT-proBNP, albumin <2.5, lower CD34, no rest: https://t.co/HfHWLHUz8Y. #mmsm

[EBMT @TheEBMT]

💡 Have you seen this recent publication in @BMTjournal?

📰 Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee ⬇️
https://t.co/vLES14K7Xp

👥 Guillermo Ortí, @GuillaumeDachy, Charlotte E. Graham, Zinaida Peric, @AnaAlarconTomas, @Fra_delBufalo, Matteo Doglio, Jan-Inge Henter, @drclaireroddie, @Orlapstewart, W.C.J. Van de Donk, @VelascoRoser, @aljurf100, @AnnalisaRugger1, @OnidaFrancesco, Isabel Sánchez-Ortega, Ibrahim Yakoub-Agha & Olaf Penack

#HCT #CARTcell #celltherapy #MedTwitter

[Mohamed Kharfan-Dabaja, MD, MBA @MKD_BMT]

The largest experience of autologous hematopoietic cell transplantation in 1700 patients with autoimmune diseases, in the outpatient setting, using the “Mexican method”. “Yes, it can be done” “Si se puede”@BMTjournal @GuillermoRuizA5 @dgomezalmaguer @GomezDLeonMD

[Weill Cornell BMT Program @WeillCornellBMT]

Applications for the 2026 @WeillCornell @nyphospital advanced Bone Marrow Transplant (#BMT) and #CellularTherapy fellowship are open. Apply for the opportunity to join our team in July 2026: https://t.co/conoTLQKoZ